Constituents
Finasteride
More than ninety percent of men with hair problems are reported to have been diagnosed with male pattern baldness (androgenic alopecia, AGA). AGA is characterized by thin hair on the frontal region and the top of head. It has been known that its primary causal factor is dihydrotesosterone (DHT) that results from combining type II 5 – α reductase with testosterone. Type II 5 – α reductase is secreted from sebaceous glands on the scalp. Testosterone is a type of androgen. Excessive DHT damages roots of hair, making hair thinner.
Finasteride not just controls androgen but regulates type II 5 – α reductase, and thus, prevents testosterone from changing into DHT. This is why finasteride has been approved as a remedy for AGA. Finasteride is also known to be effective against benign prostate hyperplasia (BPH). BPH leads to prostate cancer, which is currently in increase, as well as cyctitis, uremia, and renal failure. Finasteride was approved by FDA as a preventive against these diseases in 1992 (also as a remedy for AGA in 1997). Currently it is used in more than sixty countries.
Doctors prescribe five milligrams of finasteride per day to men with benign prostate hyperplasia. With regard to AGA, only one milligram dosage per day provides adequate results for more than eighty percent of its users. Finasteride has also been shown to be a safe drug.
ΛGROW liquid and tablet formulation both contain a unique and optimal blend of finasteride. The probability of side effects, such as decline in sexual desire and erectile dysfunctions, is very minimal. Further, it has been reported that regular users of finasteride develop a resistance that makes side effects even less likely.
Finastride is contraindicated in pregnant women because it may lead to birth defects.
* Androgen
Sixty years ago AGA was found to be related to androgen as well as genetic factors. It remained unknown until recently, however, that androgen helps hair grow on some regions of human body while it causes hair loss on other regions. For example, because of the increase in release of androgen after adolescence, hair on men’s face and chest becomes firm and thick whereas growth of underarm and pubic hair is found without regard to sex. Androgen, however, has no effect on hair on the occipital area and eyebrows. According to recent studies, these are due to regional differences in sensitivity of hair papilla cells to sex hormones.
Minoxidile
Minoxidile was originally developed by Upjohn Inc. (forerunner of Pfizer Inc.) as an antihypertensive. Because of a side effect of increased hair growth, minoxidil is now used as a constituent of hair regrowth formula. In the United States, a medicine that contained 5% minoxidil was approved by Food and Drug Administration as an over-the counter or non-prescription (OTC) medicine. Currently minoxidil has been approved in ninety-five countries and sold as an OTC medicine in forty-six of these countries, including Japan.
The lifetime of normal hair is three to five years. Within its lifetime, each hair goes through the cycle of growth, decline, and dormancy several times. Androgenic alopecia, however, prevents growth of hair follicles and makes hair thinner by shortening the period of their growth. Minoxidile helps dormant hair follicles to start regrowing. It also helps blood to flow smoothly around hair tissues by expanding blood vessels. Further it promotes proliferation of hair tissues and helps hair to take in amino acids, nutrients for hair.
While minoxidil has been shown to be a safe medicine, there have been several cases that its users reported palpitations, headache, or other discomforts. Risk of these side effects can be reduced, however, by not providing minoxidil to people with some types of allergy and/or cardiovascular diseases.
Whereas finasteride and minoxidil are essential constituents of hair growth formulae, their effects vary according to their quality and blending quantity. This is why results of hair growth formulae containing finasteride and minoxidil have not been consistent. ΛGROW is formulated to maximize the main effects of these medicines without their side effects. ΛGROW controls every source of androgenic alopecia while nourishing new hair, leading to regrowth of hair after six to twelve months of use.
The lifetime of normal hair is three to five years. Within its lifetime, each hair goes through the cycle of growth, decline, and dormancy several times. Androgenic alopecia, however, prevents growth of hair follicles and makes hair thinner by shortening the period of their growth. Minoxidile helps dormant hair follicles to start regrowing. It also helps blood to flow smoothly around hair tissues by expanding blood vessels. Further it promotes proliferation of hair tissues and helps hair to take in amino acids, nutrients for hair.
While minoxidil has been shown to be a safe medicine, there have been several cases that its users reported palpitations, headache, or other discomforts. Risk of these side effects can be reduced, however, by not providing minoxidil to people with some types of allergy and/or cardiovascular diseases.
Whereas finasteride and minoxidil are essential constituents of hair growth formulae, their effects vary according to their quality and blending quantity. This is why results of hair growth formulae containing finasteride and minoxidil have not been consistent. ΛGROW is formulated to maximize the main effects of these medicines without their side effects. ΛGROW controls every source of androgenic alopecia while nourishing new hair, leading to regrowth of hair after six to twelve months of use.